Ocular inflammation is the 4th leading cause of blindness among the working-age population in the developed world. Macular edema secondary to inflammation (MESI) is a serious complication of ocular inflammation and the primary contributor to vision loss and blindness in this group. Learn more about #MESI at Kodiak.com: https://lnkd.in/gS4nmPYz
Kodiak Sciences
Biotechnology Research
Palo Alto, California 11,620 followers
We are a precommercial retina focused biotech bringing new science to prevent and treat the leading causes of blindness
About us
Kodiak is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead investigational medicine, tarcocimab, is a novel anti-VEGF antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases. KSI-501 is our second investigational medicine, a first-in-class anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate designed to inhibit both IL-6 mediated inflammation and VEGF-mediated angiogenesis and vascular permeability. KSI-501 is being developed for the treatment of high prevalence retinal vascular diseases to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. KSI-101, our third product candidate, is a novel anti-IL-6, VEGF-trap bispecific protein for the treatment of retinal inflammatory diseases. We are advancing our platform technology to embed small molecules and other active pharmaceutical ingredients for multifactorial diseases. WORKING AT KODIAK We foster a culture of curiosity, creativity, compassion and courage. Our collective goal is to make a difference in the world. We do that as a team driven by the shared desire to tackle some of the world’s biggest challenges. If this sounds exciting, we want to hear from you! Kodiak supports a vibrant and active lifestyle, striving to provide an optimal work-life balance. We are located in Palo Alto, in the heart of the world-class biotech hub of Silicon Valley, and within walking distance to California Avenue’s shops, restaurants and public transportation.
- Website
-
http://www.kodiak.com
External link for Kodiak Sciences
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Palo Alto, California
- Type
- Public Company
- Founded
- 2009
Locations
-
Primary
Get directions
1250 Page Mill Rd
Palo Alto, California 94304, US
Employees at Kodiak Sciences
Updates
-
We are proud to announce the first presentation of interim results from the APEX study of KSI-101 at this year’s EURetina congress, presented by Dr. Charles Wykoff on behalf of Kodiak Sciences. KSI-101 is a novel, potent and high strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF. We are developing KSI-101 for patients with macular edema (retinal fluid) secondary to inflammation (MESI). MESI is a heterogenous group of diseases that clinically present with macular edema and visual impairment which are caused by a common pathophysiology–inflammation and blood retinal barrier disruption. The clinical presentation of retinal fluid and visual impairment is a mainstay in these patients, irrespective of the location of the inflammation inside of the eye (anterior, intermediate, posterior or all intraocular compartments) or the specific etiology (uveitic macular edema, idiopathic macular edema, post-procedural macular edema, inflammatory choroidal neovascularization). Currently there are no available intravitreal biologic therapies addressing the spectrum of MESI diseases. 👉 The full presentation is available on our website: https://lnkd.in/gNHiy_cf 👏🏻 A big thank you to Dr. Wykoff, our clinical investigators, the Kodiak team and the patients who make this important research possible #EURetina2025 #Retina #MacularEdema #KSI101
-
Join us at 9:20am ET on Thursday, June 5! Victor Perlroth, M.D., Chief Executive Officer will present details about Kodiak’s maturing pipeline of three late-stage clinical assets across a broad spectrum of retinal diseases. All three assets are targeting Phase 3 topline data in 2026. #JefferiesHealthcare A link to the webcast can be found here: https://lnkd.in/g4_be5Gw
-
-
3…2…1…action! "In September of 2024 we hosted an Investor R&D Day in New York," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The Investor R&D Day webcast and presentation featured scientific, clinical and commercial perspectives and included key retina opinion leaders. It was an important snapshot of where we stood at that time, and where we were going – we called it Kodiak 2.0. Six months later, we are well on track." To learn more about Kodiak’s recent accomplishments and upcoming catalysts across our clinical programs and pipeline, read our recent business highlights and fourth quarter and full year 2024 financial results press release here: https://lnkd.in/gJ9zeATK
-
-
Enrollment is complete in our second registrational study of tarcocimab in patients with diabetic retinopathy! “Fewer than 1% of subjects with diabetic retinopathy are treated today due to high treatment burden associated with frequent injections needed with today’s approved therapies. If diabetic retinopathy is left untreated, the majority of patients - and this is millions of patients - will experience disease progression and develop vision-threatening complications,” said Dr. Allen Hu. “If GLOW2 mirrors these results [GLOW1 study results], I believe tarcocimab as a biologic with twice yearly dosing in all patients can change the treatment landscape in diabetic retinopathy and help millions of patients,” concluded Dr Hu. Read the press release here: https://lnkd.in/gi5-J8sp
-
-
Join us at 3:00pm PT today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. We look forward to sharing the progress of our rapidly advancing pipeline, including new clinical data on KSI-101, a first-in-class bispecific protein for the treatment of macular edema secondary to inflammation. View webcast here: https://lnkd.in/gJ2xfr9r
-